The current COVID-19 pandemic challenges oncologists to profoundly re-organize
oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced …

Background Previous studies have demonstrated the efficacy and safety of bevacizumab in
the treatment of non-small-cell lung cancer (NSCLC). Methods Summary data from …

… This enzyme has a tetrameric structure composed of LDH-A and LDH-B subunits with five
isoforms known to exist owing to different combinations of LDH-A and LDH-B. Several distinct …

Background In single-group studies, chromosomal rearrangements of the anaplastic lymphoma
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …

Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …

Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis 1 ,
2 , 3 . We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an …

Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to
treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across …

… b, Kernel density estimation aligning two variables, OS < or ≥ 12 months and relative …
hallii or B. adolescentis was found to accurately predict ORR and/or mOS in this cohort of …

Background Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …

… had received an investigational anticancer drug within 14 days or 5 half-lives of start of
therapy (minimum 14 days), those with active gastrointestinal disease, and those with hepatitis B …